Asymchem Laboratories (Tianjin) Co., Ltd.
002821
Rangering i aksjer
#2511
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development... Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
Aksjekurs
$20.91
Markedsverdi
$7.57B
Endring (1 dag)
-8.26%
Endring (1 år)
41.25%
Land
CN
Handel Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
Kategori
Healthcare
Inntekter for Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
Inntekter i Jun 2026 TTM: $1.06B
Ifølge de nyeste økonomiske rapportene til Asymchem Laboratories (Tianjin) Co., Ltd. er selskapets nåværende inntekter (TTM) $1.06B. I 2024 hadde selskapet inntekter på $795.26M en nedgang sammenlignet med inntektene i 2023, som var $1.11B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Asymchem Laboratories (Tianjin) Co., Ltd. fra 2011 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.06B | 11.34% |
| 2025 | $953.37M | 19.88% |
| 2024 | $795.26M | -28.06% |
| 2023 | $1.11B | -25.46% |
| 2022 | $1.48B | 103.50% |
| 2021 | $728.79M | 51.78% |
| 2020 | $480.16M | 35.91% |
| 2019 | $353.28M | 32.44% |
| 2018 | $266.75M | 21.96% |
| 2017 | $218.72M | 37.65% |
| 2016 | $158.90M | 24.23% |
| 2015 | $127.91M | 10.62% |
| 2014 | $115.63M | 29.23% |
| 2013 | $89.48M | 31.47% |
| 2012 | $68.06M | 5.76% |
| 2011 | $64.35M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 1,089.29% |
US
|
|
| $2.23B | 109.89% |
US
|
|
| $15.74B | 1,383.22% |
AU
|
|
| $9.57B | 801.80% |
BE
|
|
| $6.02B | 467.25% |
NL
|
